Tyra Biosciences (TYRA) Chief Discovery Officer reports preset stock sales

Rhea-AI Filing Summary

Tyra Biosciences Chief Discovery Officer Bensen Daniel reported preset insider stock sales. On January 12, 2026, he sold 6,983 shares of Tyra Biosciences common stock at a weighted average price of $28.442 and an additional 1,017 shares at a weighted average price of $29.0808, both listed as open-market sales. These trades were carried out under a Rule 10b5-1 trading plan adopted on November 5, 2024, which is designed to pre-schedule transactions. After these sales, Daniel beneficially owned 154,981 shares of Tyra Biosciences common stock in direct ownership.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Bensen Daniel

(Last) (First) (Middle)

C/O TYRA BIOSCIENCES, INC.

2656 STATE STREET

(Street)

CARLSBAD CA 92008

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Tyra Biosciences, Inc. [ TYRA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Discovery Officer

3. Date of Earliest Transaction (Month/Day/Year)
01/12/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	01/12/2026		S(1)		6,983	D	$28.442(2)	155,998	D
Common Stock	01/12/2026		S(1)		1,017	D	$29.0808(3)	154,981	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 5, 2024.

2. Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range between $27.9083 to $28.84. Detailed information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.

3. Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range between $28.9131 to $29.23. Detailed information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.

	/s/ Ali D. Fawaz, Attorney-in-Fact	01/20/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did TYRA executive Bensen Daniel report?

Chief Discovery Officer Bensen Daniel reported selling shares of Tyra Biosciences, Inc. common stock in two open-market transactions dated January 12, 2026.

How many Tyra Biosciences (TYRA) shares did the insider sell and at what prices?

He sold 6,983 shares at a weighted average price of $28.442 and 1,017 shares at a weighted average price of $29.0808, as disclosed in the Form 4.

How many TYRA shares does Bensen Daniel own after the reported transactions?

Following the reported sales, Bensen Daniel beneficially owned 154,981 shares of Tyra Biosciences common stock, held in direct ownership.

Was the TYRA insider sale made under a Rule 10b5-1 trading plan?

Yes. The filing states the sales were effected under a Rule 10b5-1 trading plan adopted by the reporting person on November 5, 2024.

Who is the reporting person in this Tyra Biosciences (TYRA) Form 4 filing?

The reporting person is Bensen Daniel, who serves as Chief Discovery Officer of Tyra Biosciences, Inc..

What price range did the TYRA insider sales cover on January 12, 2026?

The footnotes state the actual sale prices ranged from $27.9083 to $28.84 for one trade and from $28.9131 to $29.23 for the other, with weighted average prices reported in the table.